Skip to content

Study · Systematic review · 2026

5 results

Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review.

Omeh Z, Khan T, Uthman O, Barber TM

Expert review of endocrinology & metabolism12 Apr 2026

PMID41968780 (opens in a new tab)DOI10.1080/17446651.2026.2656247 (opens in a new tab)PepBankPUB-41968780
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with obesity, the network review reported statistically equivalent weight-loss efficacy for tirzepatide 10 or 15 mg and sleeve gastrectomy.

    In plain wordsIn adults with obesity, the review reported similar weight-loss efficacy for tirzepatide 10 or 15 mg and sleeve gastrectomy.

    Peptide
    Tirzepatide
    Outcome
    Not applicablePercentage total body weight loss
    Study

    n: not reported in source

    Comparator
    Sleeve gastrectomy
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 or 15 mgAs given in this study (human).

    Source sentences

    Summary
    SG (MD 21.1% TWL, 95% CI 14.2% to 28.0%) and Tirzepatide 10 or 15 mg (MD 21.3% TWL, 95% CI 17.3% to 25.2%) demonstrated statistically equivalent weight-loss efficacy (P-score: 0.84) and had the most favorable effectiveness profiles.
    5 context sentences
    Summary · context
    Systematic review and network meta-analysis of randomized controlled trials.
    Summary · context
    MEDLINE, EMBASE, and Cochrane CENTRAL databases were searched between 2014 and 2024 for trials comparing sleeve gastrectomy (SG), Tirzepatide and other pharmacotherapies to control or each other.
    Summary · context
    Eligible studies: adults with obesity and weight loss outcomes ≥24 weeks.
    Summary · context
    Primary outcome: percentage change total body weight.
    Summary · context
    Interventions ranked by: P-score, mean difference (MD), 95% confidence intervals (CI).
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with obesity, semaglutide 2.4 mg had a network mean difference of 12.7% total weight loss.

    In plain wordsIn adults with obesity, semaglutide 2.4 mg had a 12.7% network mean difference in total weight loss.

    Peptide
    Semaglutide
    Outcome
    DecreasePercentage total body weight loss
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mgAs given in this study (human).

    Measurements

    Network mean difference in total weight loss
    12.7%
    semaglutide 2.4 mg; reference comparator not stated

    Source sentences

    Summary
    Semaglutide 2.4 mg (MD 12.7% TWL) and Liraglutide 3.0 mg (MD 5.1% TWL) showed moderate efficacy, whilst Orlistat showed minimal effect (MD 2.7% TWL, 95% CI -4.2% to 9.6%).
    5 context sentences
    Summary · context
    Systematic review and network meta-analysis of randomized controlled trials.
    Summary · context
    MEDLINE, EMBASE, and Cochrane CENTRAL databases were searched between 2014 and 2024 for trials comparing sleeve gastrectomy (SG), Tirzepatide and other pharmacotherapies to control or each other.
    Summary · context
    Eligible studies: adults with obesity and weight loss outcomes ≥24 weeks.
    Summary · context
    Primary outcome: percentage change total body weight.
    Summary · context
    Interventions ranked by: P-score, mean difference (MD), 95% confidence intervals (CI).
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with obesity, liraglutide 3.0 mg had a network mean difference of 5.1% total weight loss.

    In plain wordsIn adults with obesity, liraglutide 3.0 mg had a 5.1% network mean difference in total weight loss.

    Peptide
    Liraglutide
    Outcome
    DecreasePercentage total body weight loss
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mgAs given in this study (human).

    Measurements

    Network mean difference in total weight loss
    5.1%
    liraglutide 3.0 mg; reference comparator not stated

    Source sentences

    Summary
    Semaglutide 2.4 mg (MD 12.7% TWL) and Liraglutide 3.0 mg (MD 5.1% TWL) showed moderate efficacy, whilst Orlistat showed minimal effect (MD 2.7% TWL, 95% CI -4.2% to 9.6%).
    5 context sentences
    Summary · context
    Systematic review and network meta-analysis of randomized controlled trials.
    Summary · context
    MEDLINE, EMBASE, and Cochrane CENTRAL databases were searched between 2014 and 2024 for trials comparing sleeve gastrectomy (SG), Tirzepatide and other pharmacotherapies to control or each other.
    Summary · context
    Eligible studies: adults with obesity and weight loss outcomes ≥24 weeks.
    Summary · context
    Primary outcome: percentage change total body weight.
    Summary · context
    Interventions ranked by: P-score, mean difference (MD), 95% confidence intervals (CI).
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with obesity, tirzepatide 10 or 15 mg had a network total-weight-loss mean difference of 21.3% (95% CI 17.3%–25.2%), with the reference comparator unstated.

    In plain wordsIn adults with obesity, tirzepatide 10 or 15 mg had a 21.3% network mean difference in total weight loss; the reference comparator was unstated.

    Peptide
    Tirzepatide
    Outcome
    DecreaseNetwork mean difference in total weight loss
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 or 15 mgAs given in this study (human).

    Measurements

    Network mean difference in total weight loss
    21.3%
    tirzepatide 10 or 15 mg; 95% CI 17.3–25.2; reference comparator unstated

    Source sentences

    Summary
    SG (MD 21.1% TWL, 95% CI 14.2% to 28.0%) and Tirzepatide 10 or 15 mg (MD 21.3% TWL, 95% CI 17.3% to 25.2%) demonstrated statistically equivalent weight-loss efficacy (P-score: 0.84) and had the most favorable effectiveness profiles.
    5 context sentences
    Summary · context
    Systematic review and network meta-analysis of randomized controlled trials.
    Summary · context
    MEDLINE, EMBASE, and Cochrane CENTRAL databases were searched between 2014 and 2024 for trials comparing sleeve gastrectomy (SG), Tirzepatide and other pharmacotherapies to control or each other.
    Summary · context
    Eligible studies: adults with obesity and weight loss outcomes ≥24 weeks.
    Summary · context
    Primary outcome: percentage change total body weight.
    Summary · context
    Interventions ranked by: P-score, mean difference (MD), 95% confidence intervals (CI).
  5. 05HumanSystematic reviewSafety outcome

    In adults with obesity, the network review ranked semaglutide 2.4 mg among pharmacotherapies with the most favorable adverse-event safety profiles.

    In plain wordsIn adults with obesity, the review ranked semaglutide 2.4 mg among pharmacotherapies with the most favorable safety profiles.

    Peptide
    Semaglutide
    Outcome
    Not applicableSafety profile
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body
    Studied dose
    2.4 mgAs given in this study (human).

    Source sentences

    Summary
    Network meta-analysis of adverse events demonstrated that Semaglutide 2.4 mg and Orlistat had the most favorable safety profiles amongst pharmacotherapies.
    4 context sentences
    Summary · context
    Systematic review and network meta-analysis of randomized controlled trials.
    Summary · context
    MEDLINE, EMBASE, and Cochrane CENTRAL databases were searched between 2014 and 2024 for trials comparing sleeve gastrectomy (SG), Tirzepatide and other pharmacotherapies to control or each other.
    Summary · context
    Eligible studies: adults with obesity and weight loss outcomes ≥24 weeks.
    Summary · context
    Secondary outcomes included adverse events.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Versions 2 to 3

    9 Oct 2026, 03:07 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.